Riluzole
Who holds supplier records for Riluzole? 6 organisations hold a current record for Riluzole: an active US FDA Type II Drug Master File. A further 3 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (4) and Taiwan (2).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Riluzole: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/riluzole
Reading the evidence
- 6 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
4 of the 6 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Riluzole expires 12 Mar 2029. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (6)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Riluzole. Country is the organisation's recorded country, not necessarily the manufacturing site.
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 22107 · latest filing Oct 2008
- Alkem Laboratories LimitedIndia Company GMP cert on recordActive DMF 25260 · latest filing Sept 2011
- Hetero Drugs LimitedIndia Company GMP cert on recordActive DMF 23215 · latest filing Oct 2009
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 15252 · latest filing Jan 2001
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 22438 · latest filing Mar 2009
- SYN-TECH CHEM AND PHARM CO LTDTaiwanActive DMF 26147 · latest filing Jun 2012
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (3)
Organisations whose Type II DMFs for Riluzole are no longer active. These show a past filing, not current supply.
Show all 3 historical records
- ESTEVE QUIMICA SAInactive DMF 24693 · filed Feb 2011
- India · Inactive DMF 23569 · filed Feb 2010
- Apotex Pharmachem India Pvt. Ltd.India · Inactive DMF 22596 · filed Mar 2009
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (6 listed products contain Riluzole). The latest listed patent expires 12 Mar 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Riluzole is a drug that modulates glutamatergic neurotransmission and is primarily used in the treatment of amyotrophic lateral sclerosis (ALS), a disease that affects the nerve cells in the brain and spinal cord. It works by diminishing the release of glutamate, which is often associated with the neurodegenerative processes in ALS.
Chemical identity
- IUPAC name
- 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
- Canonical SMILES
- C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
- InChIKey
- FTALBRSUTCGOEG-UHFFFAOYSA-N
- Synonyms
- Rilutek API, bhv-0223, exservan, nsc-753433, nsc-759823, rilutek, rp 54274, rp-54274, tiglutik
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Benzothiazole
- Chemical structure
- Benzothiazoles
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Riluzole?
6 organisations hold an active US FDA Type II Drug Master File or a CEP for Riluzole: ALIVUS LIFE SCIENCES LTD (India), Alkem Laboratories Limited (India), Hetero Drugs Limited (India), SCINOPHARM TAIWAN LTD (Taiwan), Sun Pharmaceutical Industries Limited (India) and SYN-TECH CHEM AND PHARM CO LTD (Taiwan). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Riluzole Drug Master Files are active?
ALIVUS LIFE SCIENCES LTD (DMF 22107), Alkem Laboratories Limited (DMF 25260), Hetero Drugs Limited (DMF 23215), SCINOPHARM TAIWAN LTD (DMF 15252), Sun Pharmaceutical Industries Limited (DMF 22438) and SYN-TECH CHEM AND PHARM CO LTD (DMF 26147). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Riluzole records mean?
3 organisations have only inactive Type II DMFs for Riluzole. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Riluzole?
Yes. The latest patent listed for an approved US product containing Riluzole expires 12 Mar 2029, across 6 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Riluzole supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Riluzole?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.